Zynerba Provides Clinical Update for Lead Development …

Phase 1 clinical trial for ZYN001 is expected to begin in 1H17

Topline results for three Phase 2 clinical trials for ZYN002 are on track for 1H17

DEVON, Pa., Oct. 17, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today provided a development update for ZYN001 and ZYN002.

Zynerba and its development partner, LTS LOHMANN Therapie-Systeme AG (LTS), a market leader in transdermal therapeutic solutions, are working together to optimize the formulation of ZYN001 into a state of the art drug-adhesive matrix transdermal patch. ZYN001 is a patent-protected pro-drug of THC being developed for the treatment of fibromyalgia and peripheral neuropathic pain. Based on the additional optimization work in progress, Zynerba now expects to begin Phase 1 clinical trials for ZYN001 in the first half of 2017 and

... read more at: http://globenewswire.com/news-release/2016/10/17/879911/0/en/Zynerba-Provides-Clinical-Update-for-Lead-Development-Candidates-ZYN001-and-ZYN002.html